|
|
||||||||
CUTTING EDGE |


*
Institut National de la Santé et de la Recherche Médicale U448, Henri Mondor Hospital, Faculté de Medecine, Créteil, France;
Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;
Institut National de la Santé et de la Recherche Médicale U395, Purpan University Hospital, Toulouse, France;
§
Coulter Technology Center, Miami, FL 33196; and
¶
Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
BY55 is a human cell surface molecule whose expression is restricted to NK cells, a subset of circulating CD8+ T lymphocytes, and all intestinal intraepithelial T lymphocytes. Here, we report that BY55 is a novel NK receptor showing broad specificity for both classical and nonclassical MHC class I molecules, and that optimal binding requires a prior aggregation of MHC class I complexes. Using BY55 transfectants, we have identified functional consequences of MHC class I/ligand interactions for the class I-bearing cell. The triggering of MHC class I molecules on human T cell clones by BY55 delivered a potent proliferative signal in the presence of soluble CD3 mAb. The costimulatory signal provided by MHC class I ligation was only seen in activated, and not resting, peripheral blood T cells. This observation represents an additional and/or alternative pathway to CD28 costimulation and may be of particular relevance in memory T cells lacking CD28, such as intestinal intraepithelial T lymphocytes, which are CD28- but BY55+.
This article has been cited by other articles:
![]() |
J. Giustiniani, A. Marie-Cardine, and A. Bensussan A Soluble Form of the MHC Class I-Specific CD160 Receptor Is Released from Human Activated NK Lymphocytes and Inhibits Cell-Mediated Cytotoxicity J. Immunol., February 1, 2007; 178(3): 1293 - 1300. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Fons, S. Chabot, J. E. Cartwright, F. Lenfant, F. L'Faqihi, J. Giustiniani, J.-P. Herault, G. Gueguen, F. Bono, P. Savi, et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells Blood, October 15, 2006; 108(8): 2608 - 2615. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Maeda, C. Carpenito, R. C. Russell, J. Dasanjh, L. L. Veinotte, H. Ohta, T. Yamamura, R. Tan, and F. Takei Murine CD160, Ig-Like Receptor on NK Cells and NKT Cells, Recognizes Classical and Nonclassical MHC Class I and Regulates NK Cell Activation J. Immunol., October 1, 2005; 175(7): 4426 - 4432. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Barakonyi, M. Rabot, A. Marie-Cardine, M. Aguerre-Girr, B. Polgar, V. Schiavon, A. Bensussan, and P. Le Bouteiller Cutting Edge: Engagement of CD160 by its HLA-C Physiological Ligand Triggers a Unique Cytokine Profile Secretion in the Cytotoxic Peripheral Blood NK Cell Subset J. Immunol., November 1, 2004; 173(9): 5349 - 5354. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Le Bouteiller, A. Barakonyi, J. Giustiniani, F. Lenfant, A. Marie-Cardine, M. Aguerre-Girr, M. Rabot, I. Hilgert, F. Mami-Chouaib, J. Tabiasco, et al. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity PNAS, December 24, 2002; 99(26): 16963 - 16968. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nikolova, A. Marie-Cardine, L. Boumsell, and A. Bensussan BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression Int. Immunol., May 1, 2002; 14(5): 445 - 451. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. I. Slukvin, D. P. Lunn, D. I. Watkins, and T. G. Golos Placental expression of the nonclassical MHC class I molecule Mamu-AG at implantation in the rhesus monkey PNAS, August 1, 2000; 97(16): 9104 - 9109. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Poszepczynska, M. Bagot, H. Echchakir, D. Martinvalet, M. Ramez, D. Charue, L. Boumsell, and A. Bensussan Functional characterization of an IL-7-dependent CD4+CD8alpha alpha + Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma Blood, August 1, 2000; 96(3): 1056 - 1063. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |